Tissues in the body work as a complex team of interconnected cells. For instance, the heart is comprised of contractile cardiomyocytes, along with a vast array of endothelial cells, immune cells and fibroblasts. Similarly, the liver includes hepatocytes, immune cells, endothelial cells and epithelial cells. Put in all the cellular players, and the team wins. Take out one player, and the team is no longer able to sufficiently function.
The field of 3D bioprinting draws deeply on this idea of optimizing tissue regeneration and replacement. By using naturally-derived scaffolds, human cells and other biocompatible materials, 3D bioprinting has ushered in opportunities for researchers to design, print and optimize patient personalized tissues for purposes ranging from transplantation to drug testing.
The current drug development process is extremely lengthy and costly due to the lack of proper tools for preclinical drug screening, said Dr. Wei Zhu, CEO of Allegro 3D, a San Diego-based bioprinting company. What excites us most about 3D bioprinting is its potential to provide a paradigm shift in the drug discovery and screening process.
The bioprinting process is analogous to a Build-A-Bear factory but while a teddy bear contains carefully chosen ribbons, buttons and stuffing, 3D bioprinting creates complex tissues possibly derived from a patients own cells. In both cases, integrating customized components allows for layer-by-layer formation of something unique, yet fully functional.
While the techniques used for 3D bioprinting have mechanical grounding in traditional printing, the defining characteristic of 3D bioprinting is the usage of bioinks. Bioinks are complex, optimized mixtures of solution matrices containing carrier molecules and additional supporting agents. Often, the solution material is a biopolymer a naturally-derived gel, used to envelop the cells as a 3D molecular scaffold. Common biomaterials include gelatin, hyaluronic acid and alginate, all of which retain a high degree of biocompatibility. They provide a supporting structure, as well as a nurturing environment for future cellular growth and differentiation.
Historically, 3D bioprinting has become possible through three main modalities: light-based bioprinting, inkjet bioprinting and extrusion based bioprinting. Light-based bioprinting utilizes a light source, which can often be a blue LED, to cure photo-polymerizable bioinks into a more solidified scaffold. Inkjet bioprinting, on the other hand, is analogous to the conventional desktop printer, where bioink droplets are positioned on a receiving substrate based on computer control. Finally, extrusion based bioprinting relies on pressure to mechanically dispense bioinks by syringe extrusion onto receiving substrates.
Each technique has its own unique advantages. For example, light-based bioprinting allows for an incredible degree of precision, resolution and speed resulting in the possibility of micro or nanopatterning in a rapid fashion. Inkjet or droplet bioprinting is markedly straightforward, with low overall production costs and easy handling. Extrusion-based printing allows for printing with high cell densities.
Allegro 3D finds its niche in the bioprinting industry by providing light-based printing products primarily, their StemakerTMbioprinter and SteminkTMbioinks. Notably, the StemakerTMbioprinter was the worlds first digital light processing (DLP) bioprinter for high throughput tissue printing. Light is applied to the pre-polymer bioink, which photopolymerizes layer-by-layer to encapsulate live cells in the final 3D tissue construct. By using visible light as the photopolymerization source, cell viability remains very high during the manufacturing process. Furthermore, the technique allows for incorporation of various cell types in a single printed scaffold for instance, liver cells in the bottom layer, and endothelial cells in the top layer. With the ability to mix and match various cell types, the complexity and diversity of human tissues is an achievable possibility.
In terms of application, the possibilities of Allegro 3Ds bioprinting techniques have dramatic implications for the biomedical community.
With our StemakerTMbioprinters and SteminkTMbioinks, our customers can print 3D precision human tissues on demand for various biomedical applications, Zhu said. These applications include building tissue samples for disease modeling, providing patient-specific tissues or organs for therapeutic treatment of injuries, and providing 3D human tissues to investigate the toxicity and efficacy of new drug compounds in vitro.
By closely mimicking hepatic lobule structure through an eye-catching pattern of hexagons and circles that looks somewhat like a bees hive, this DLP bioprinter was able to print human liver tissue containing both human induced pluripotent derived stem cells and other supporting cells in seconds. The goal of such constructs would then be to provide easily accessible tissues for high-throughput drug discovery, or to print patient-derived hepatic tissues for liver regeneration.
According to Zhu, a key issue with traditional bioprinting techniques is that of scalability. Pharmaceutical and biotechnology industries often use high-throughput screening instruments for which the needs far exceed the capabilities of traditional bioprinters. The photopolymerization techniques of the StemakerTMbioprinter allow for compatibility with the high-throughput systems, which will greatly help our customers improve the accuracy and efficiency of drug screening and assay development.
On the extrusion-based bioprinting front, Allevi, a 3D bioprinting company based in Philadelphia, focuses on providing universally-friendly extrusion-based bioprinters, bioinks and software. Their latest model, named Allevi 3, contains three extruders through which bioinks can be deposited to form tissue scaffolds. Allevi also offers a wide selection of bioinks, which can be mixed in conjunction with cell populations to be directly utilized in their 3D bioprinters.
Likewise, Cellink, which was the first company to commercialize bioinks, is a Boston-based bioprinting company that has since expanded to provide services ranging from bioprinters to live cell imaging and liquid handling machines. Cellinks bioprinters include extrusion-based printers that contain up to six extruder heads with the BIO X6, as well as light-based printers. Their vast array of automated systems represents a diverse amalgamation of capabilities for more streamlined manufacturing.
Altogether, these 3D bioprinting companies represent a rapidly growing sector of the biotechnology industry. The unmet medical need of human tissue for regeneration, drug testing, and other pharmaceutical purposes remains a key driving force. 3D bioprinting has potential to change the ways in which we discover new, exciting chemical compounds to treat debilitating diseases, or to eliminate the strenuous waiting game experienced by many in need of an organ transplant. With the advent of these technologies, we acknowledge a future where we may potentially design, print and order complex human tissues for life-saving purposes.
View original post here:
Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry - BioSpace
- Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock - The Scientist - March 13th, 2024
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy - Nature.com - March 3rd, 2024
- Breaking through new research barriers with iPSC technology - News-Medical.Net - February 15th, 2024
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 12th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 12th, 2024
- Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for ... - Nature.com - December 23rd, 2023
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming - Nature.com - December 15th, 2023
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 13th, 2023
- CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes ... - Nature.com - December 7th, 2023
- World Hindu Congress 2023: Know all about the sessions and speakers - Organiser - November 23rd, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS ... - Business Wire - November 21st, 2023
- Efficient protocol for the differentiation of kidney podocytes from ... - Nature.com - November 17th, 2023
- Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com - November 17th, 2023
- Study reveals the critical role of microglia in human brain development - Medical Xpress - November 15th, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through... - November 15th, 2023
- Who are the leading innovators in iPSCs for the pharmaceutical ... - Pharmaceutical Technology - November 7th, 2023
- Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous... - November 5th, 2023
- Systematic differences in discovery of genetic effects on gene ... - Nature.com - October 21st, 2023
- Pairwise biosynthesis of ion channels stabilizes excitability and ... - pnas.org - October 11th, 2023
- Scientists find multitude of genes associated with autism - The Statesman - October 9th, 2023
- Stem Cell Banking Market is Expected to Reach USD 16,474.30 ... - Digital Journal - October 7th, 2023
- Probing the individuality of cells and molecules - Open Access Government - October 5th, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Manchestertimes - October 3rd, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Business Wire - September 29th, 2023
- Less Funding to More Researchers Gets Nobel-level Results, Study ... - The Japan News - September 27th, 2023
- Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for ... - OncLive - September 20th, 2023
- DKMS BMST Foundation India and Kokilaben Hospital unite to spread awareness about the Importance of Stem Cell Donation on World Marrow Donor Day - APN... - September 18th, 2023
- Vitamin B6 is governed by the local compartmentalization of ... - Science - September 14th, 2023
- Dolly the sheep creator Ian Wilmut dies aged 79 - BBC - September 14th, 2023
- Scientist who created Dolly the sheep dies aged 79: Professor Sir Ian Wilmut passes away five years after reve - Daily Mail - September 11th, 2023
- The global kits market is expected to grow at a CAGR of 7.4% from ... - Digital Journal - September 8th, 2023
- Eterna Therapeutics Announces Initiation of Development Activities ... - PipelineReview.com - September 8th, 2023
- Tokyo: 100 Years of Urban Regeneration / Tokyo's Nihonbashi Area ... - The Japan News - August 31st, 2023
- Transcriptome-based prediction of drugs, inhibiting ... - Nature.com - August 30th, 2023
- From the birds and the bees to IVG - The Gauntlet - August 26th, 2023
- Breakthrough creates stem cells without any memories - Freethink - August 26th, 2023
- Aging impairs the neurovascular interface in the heart - Science - August 26th, 2023
- For This Venture Capitalist, Research on Aging Is Personal; 'Bob ... - The Wall Street Journal - August 22nd, 2023
- Unleashing Potential: Illuminating the Future of Healthcare through Revolutionary Induced Pluripotent Stem Cel - openPR - August 18th, 2023
- A 'memory wipe' for stem cells may be the key to better therapies - The Conversation - August 16th, 2023
- Erasing epigenetic 'memory' to improve the quality of stem cells - FierceBiotech - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Business Wire - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Valdosta Daily Times - August 11th, 2023
- Advancing Clinical Trials with iPSC-Derived Liver Organoids - Microbioz India - August 11th, 2023
- Activation of cAMP (EPAC2) signaling pathway promotes hepatocyte ... - Nature.com - August 1st, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapys Ability to Create New Skeletal... - July 30th, 2023
- Femtech in Japan: An Industry on the Rise - Femtech Insider - July 28th, 2023
- Association between enhanced carbonyl stress and decreased ... - Nature.com - July 28th, 2023
- Defects in early synaptic formation and neuronal function in Prader ... - Nature.com - July 27th, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of ... - Business Wire - July 25th, 2023
- Cure to Autism and Alzheimer's May Be in Space, Says 1st Brazilian Scientist who Will Be on The ISS - Folha de S.Paulo - July 25th, 2023
- Futurama's Resurrection Ruins The Perfect Ending (& Shows Must ... - Looper - July 25th, 2023
- University Of Massachusetts Amherst's Team Bags Honour Of 2023 Armstrong Fund For Science Award - India Education Diary - July 20th, 2023
- Scientists working on IVG, a new reproductive method that can make human babies in labs - IndiaTimes - July 19th, 2023
- Co-transplantation of autologous Treg cells in a cell therapy for ... - Nature.com - July 13th, 2023
- Magic Valley and Biocellion Join Forces to Improve Bioreactor Tech ... - vegconomist - the vegan business magazine - July 13th, 2023
- IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ... - Tullahoma News and Guardian - July 10th, 2023
- Hitachi : forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT - Marketscreener.com - July 6th, 2023
- Cell therapy limitations with iPS-based multi-cell therapeutics - Drug Target Review - July 6th, 2023
- Remembering Dolly- The Clone Sheep On Her Birth Anniversary - Free Press Journal - July 4th, 2023
- Labs and Translational Research - UMass Medical School - June 28th, 2023
- Cellusion raises 2.83B series C round to progress iPS cell-derived ... - BioWorld Online - June 14th, 2023
- Japan-based Fujifilm introduces first-of-its-kind human iPSC-derived ... - BSA bureau - June 6th, 2023
- ALS: Parkinson's drug ropinirole may be an effective treatment - Medical News Today - June 4th, 2023
- Scientists predict lab-grown babies in five years - Kidspot - June 4th, 2023
- Lab-grown babies could become a reality within five years - Earth.com - May 26th, 2023
- Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month - ZAWYA - May 24th, 2023
- Long-Awaited Ax-2 Mission Launches, Heads to Space Station - AmericaSpace - May 22nd, 2023
- Eterna Therapeutics and Factor Bioscience Announce New Data on ... - GlobeNewswire - May 17th, 2023
- Research Assistant job with UNITED ARAB EMIRATES ... - Times Higher Education - May 10th, 2023
- Regulation of synaptic connectivity in schizophrenia spectrum by ... - Nature.com - April 29th, 2023
- Researchers Discover Key Role of Glucose in Brain Activity - Laboratory Equipment - April 25th, 2023
- Structure of Huntington's Protein Revealed - Technology Networks - April 21st, 2023
- Study of brain immune cell infection may explain long COVID ... - NHK WORLD - April 19th, 2023
- The Mechanism That Regulates Activity of Memory Gene - Neuroscience News - April 19th, 2023
- The IPO Buzz: CytoMed Therapeutics Prices its Micro-Cap IPO at ... - IPOScoop - April 19th, 2023
- Macomics Presents its ENIGMAC Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR - Yahoo Finance - April 19th, 2023
- Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ... - Nature.com - April 19th, 2023
- A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves ... - pnas.org - April 16th, 2023
- Japan further promotes medical applications of induced pluripotent ... - BSA bureau - April 14th, 2023
Recent Comments